Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial

February 17, 2023

From Bristol Myers Squibb

Via Business Wire

Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms

February 16, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

February 03, 2023

From Bristol Myers Squibb

Via Business Wire

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

February 10, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

February 02, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia

January 27, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

January 27, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

January 26, 2023

From Bristol Myers Squibb

Via Business Wire

The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million

January 19, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference

January 03, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York

January 03, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023

December 15, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio

December 12, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend Increase

December 08, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

November 21, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

November 09, 2022

From Bristol Myers Squibb

Via Business Wire

Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022

November 02, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

October 31, 2022

From Bristol Myers Squibb

Via Business Wire

New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis

October 26, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Reports Third Quarter Financial Results for 2022

October 25, 2022

From Bristol Myers Squibb

Via Business Wire

The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program

October 25, 2022

From Bristol Myers Squibb

Via Business Wire

New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period

October 24, 2022

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy

October 21, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma

October 19, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022

October 07, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

September 16, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

September 15, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend

September 14, 2022

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

September 10, 2022

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

September 09, 2022

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Bristol Myers Squibb

Starting at /week.